Researchers from Genethon, the AFM-Téléthon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy. Indeed, after injecting microdystrophin (a “shortened” version of the dystrophin gene) via a drug vector, the researchers managed to restore muscle strength and stabilise the clinical symptoms in dogs naturally affected by Duchenne muscular dystrophy.
This work published in Nature Communications has been achieved thanks to the donations of the French Téléthon.
Teams at Genethon developed, in collaboration with a team at Royal Holloway University of London led by Pr. Dickson, and produced, a gene therapy drug combining an AAV-type viral vector with a shortened version of the dystrophin gene (approximately 4,000 base pairs), allowing the production of a functional protein. Dr Le Guiner’s team tested this innovative treatment in 12 dogs naturally affected by Duchenne muscular dystrophy. By injecting this microdystrophin intravenously, and hence into the whole body of the dogs, the researchers observed that dystrophin expression returned to a high level, and muscle function was significantly restored, with stabilisation of the clinical symptoms observed for over 2 years following injection of the drug. No immunosuppressive treatment was administered beforehand, and no sideeffects were observed.
Some Golden Retrievers develop Duchenne muscular dystrophy naturally. The successful treatment of these dogs, which show the same clinical symptoms as children with this disease, and are of a similar weight, is a decisive step toward developing the same treatment in children. “This preclinical study demonstrates the safety and efficacy of microdystrophin, and makes it possible to consider developing a clinical trial in patients. Indeed, this is the first time that it has been possible to treat the whole body of a large sized animal with this protein. Moreover, this innovative approach allows treatment of all patients with Duchenne muscular dystrophy, regardless of the genetic mutation responsible,” says Caroline Le Guiner, the main author of this study.
Learn more: Gene therapy: Microdystrophin restores muscle strength in Duchenne muscular dystrophy
The Latest on: Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Music Heals 2024 – A Decade of Healing in Support of Muscular Dystrophy Researchon May 9, 2024 at 8:41 am
Join us in celebrating the 10-year milestone of Music Heals! With love and in support of our friend Kadey Schultz and her family, and for ALL families fighting to end Duchenne Muscular Dystrophy, ...
- ASGCT 2024: Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progresson May 9, 2024 at 7:00 am
KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures.
- Dosing paused in Pfizer DMD gene therapy trial after patient deathon May 9, 2024 at 6:30 am
Pfizer is pausing dosing of its DMD gene therapy candidate in a clinical trial while investigating the death of a boy who had received it.
- Young Patient Dies After Receiving Pfizer Gene Therapyon May 9, 2024 at 6:13 am
Tragedy has struck during an important Pfizer medical trial when a young boy suffered a fatal sudden cardiac arrest after receiving experimental gene therapy, according to Reuters, and this death has ...
- 'He was a part of us' | Community mourns loss of high school football iconon May 9, 2024 at 5:35 am
Kent Spiess, 38, passed away on April 19 from a long battle with Duchenne Muscular Dystrophy. He routinely cheered on the Tigers from his wheelchair in the end zone.
- Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trialon May 7, 2024 at 11:19 pm
Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate fordadistrogene movaparvovec after acknowledging the sudden death of a young ...
- Young boy dies in trial for Pfizer Duchenne gene therapyon May 7, 2024 at 2:57 pm
A boy with Duchenne muscular dystrophy died after receiving a Pfizer experimental gene therapy. The company is pausing its trial in older boys.
- Pfizer reports patient death in Duchenne gene therapy studyon May 7, 2024 at 2:49 pm
A young patient died due to cardiac arrest after receiving Pfizer's experimental gene therapy being tested in a mid-stage trial for a muscle-wasting disorder called Duchenne muscular dystrophy(DMD), ...
- Patient dies in Pfizer study of Duchenne gene therapyon May 7, 2024 at 2:39 pm
Pfizer said the patient, a young boy who was treated earlier last year, had died suddenly. The company is working with trial researchers to investigate further.
- Pfizer’s Duchenne Gene Therapy Trial Faces Setback As Young Participant Dieson May 7, 2024 at 1:36 pm
Pzifer said the drug concerned was fordadistrogene movaparvovec (PF-06939926) an investigational gene therapy developed by the company. They added that they have stopped giving that particular dose to ...
via Google News and Bing News